<head>
<title>Core Laboratories N.V. Fourth Amended and Restated Credit Agreement</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report (Date of earliest event reported):<b>
      January 22, 2008 (January 23, 2008)</b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of registrant as specified in its charter)</p>
<p ALIGN="CENTER"><b>001-14273<br>
</b>(Commission File Number)</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<B><P>Item 1.01 Entry into Material Definitive Agreement</P>
</B><P>On January 22, 2008, Core Laboratories N.V. and certain of its subsidiaries,
entered into the Fourth Amended and Restated Credit Agreement, which we refer to as the "Amended Credit Agreement," with various financial institutions which are or may become parties to the Amended Credit Agreement (collectively, the "Lenders"), Bank of America, N.A. as administrative agent for the Lenders and as a letter of credit issuing bank. </P>
<P>The Amended Credit Agreement has been amended at the request of the
administrative agent to include certain  provisions
customary for credit facilities of this type. There were no  material
amendments or modifications to the interest rate or related margins, lending commitments, financial
covenants and related ratios, or the term
of the agreement.</P>

<P>The foregoing description does not purport to be a complete description of
the amendments or the Amended Credit Agreement and is qualified in its entirety by reference to the Amended Credit Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P>
<p>&nbsp;</p>
<b>
<p>Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits</p>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4%; PADDING-TOP: 0in" width="4%">
    <p style="TEXT-ALIGN: right" align="right"><font SIZE="2">(c)</font></td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" width="1%">
    &nbsp;</td>
    <td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 91%; PADDING-TOP: 0in" width="91%">
    <i><font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
</b>
<p>10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth&nbsp; Amended and Restated
Credit Agreement</p>
<b>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="TOP" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP"><font SIZE="2">
      <p>Dated: January 23, 2008</font></td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="TOP"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
<b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
  <tr>
    <td WIDTH="98" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="17" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="455" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="MIDDLE" style="border-bottom-style: solid; border-bottom-width: 1"><b><font SIZE="2">
      <p>EXHIBIT NO.</font></b></td>
    <td WIDTH="17" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="455" VALIGN="MIDDLE" style="border-bottom-style: solid; border-bottom-width: 1"><b><font SIZE="2">
      <p>ITEM</font></b></td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="MIDDLE" style="border-top-style: solid; border-top-width: 1">
      <p>&nbsp;</td>
    <td WIDTH="17" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="455" VALIGN="MIDDLE" style="border-top-style: solid; border-top-width: 1">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="TOP"><font SIZE="2">
      <p>10.1</font></td>
    <td WIDTH="17" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="455" VALIGN="TOP"><font SIZE="2">
      <p>Fourth Amended and Restated Credit Agreement</font></td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="17" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="455" VALIGN="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="17" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="455" VALIGN="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="98" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="17" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="455" VALIGN="TOP">&nbsp;</td>
  </tr>
</table>
</div>
</center>
<p ALIGN="left">&nbsp;</p>

</font>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_amendedrevolver.htm", "description": "8-K", "secsgml_size_bytes": 13353}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "08543546"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. Fourth Amended and Restated Credit Agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
January 22, 2008 (January 23, 2008)
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 1.01 Entry into Material Definitive Agreement
On January 22, 2008, Core Laboratories N.V. and certain of its subsidiaries,
entered into the Fourth Amended and Restated Credit Agreement, which we refer to as the "Amended Credit Agreement," with various financial institutions which are or may become parties to the Amended Credit Agreement (collectively, the "Lenders"), Bank of America, N.A. as administrative agent for the Lenders and as a letter of credit issuing bank.
The Amended Credit Agreement has been amended at the request of the
administrative agent to include certain  provisions
customary for credit facilities of this type. There were no  material
amendments or modifications to the interest rate or related margins, lending commitments, financial
covenants and related ratios, or the term
of the agreement.
The foregoing description does not purport to be a complete description of
the amendments or the Amended Credit Agreement and is qualified in its entirety by reference to the Amended Credit Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits
(c)
Exhibits
10.1        Fourth  Amended and Restated
Credit Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: January 23, 2008
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
10.1
Fourth Amended and Restated Credit Agreement